FDA Grants Priority Review to AMD Therapy.

THERAPEUTIC use of monoclonal antibodies; DISEASE progression; DRUG efficacy; BLINDNESS; RETINAL degeneration; INTRAOCULAR pressure; INJECTIONS; MONOCLONAL antibodies; EYE hemorrhage; UNITED States. Food & Drug Administration; TREATMENT effectiveness; PATHOLOGIC neovascularization; ENDOWMENTS; PATIENT safety

The article reports that the FDA granted priority review to Iveric Bio's new drug application for avacincaptad pegol to treat patients with geographic atrophy secondary to age-related macular degeneration. Topics include examines the Prescription Drug User Fee Act goal date is August 19, 2023 and considered the company stated the FDA is not currently planning to hold an Advisory Committee meeting.